Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389749 | 1.00 | GPBAR1 (0.78) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL1389747 | 1.00 | GPBAR1 (0.78) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL362360 | 1.00 | GPBAR1 (0.78) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL10290998 | 0.94 | GPBAR1 (0.77) | GPBAR1NR3C2CTSAGAA | |
| SCHEMBL1390179 | 0.93 | GPBAR1 (0.76) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL1390175 | 0.93 | GPBAR1 (0.76) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL1390178 | 0.93 | GPBAR1 (0.76) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL1390180 | 0.93 | GPBAR1 (0.76) | GPBAR1NR3C2CTSAGAAMEN1 | |
| SCHEMBL10241033 | 0.92 | GPBAR1 (0.74) | GPBAR1NR3C2CTSAGAA | |
| SCHEMBL1389615 | 0.92 | GPBAR1 (0.74) | GPBAR1NR3C2CTSAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | claimed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885NR3C2 232/4885CTSA 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.